Bupron SR is a prescription medication classified as a sustained-release formulation of bupropion. The drug is used primarily as an antidepressant and as an aid for smoking cessation. Its active ingredient bupropion works by inhibiting the reuptake of norepinephrine and dopamine in the brain. By increasing the availability of these neurotransmitters it helps to elevate mood and reduce the urge to smoke. The sustained-release design allows the medication to deliver a steady level of bupropion over an extended period. This steady delivery maintains consistent therapeutic concentrations and reduces the frequency of dosing. Physiologically the medication influences reward pathways and autonomic centers that regulate mood and nicotine dependence. Overall the drug effect supports improved emotional balance and decreases the likelihood of relapse in individuals attempting to quit smoking.

Bupron SR is a sustained release formulation of the atypical antidepressant bupropion. Its defined role is to modulate depressive symptoms and aid smoking cessation through controlled drug exposure. The medication works by inhibiting the reuptake of norepinephrine and dopamine in the central nervous system. By increasing extracellular norepinephrine and dopamine concentrations it enhances neuronal signaling that improves mood and reduces nicotine cravings. This dual reuptake inhibition differentiates it from other antidepressants that primarily target serotonin. The sustained release design allows gradual absorption leading to steadier plasma levels over several hours. Overall Bupron SR provides a pharmacologically targeted approach that influences mood regulation and addiction pathways without direct serotonergic activity.

Dry mouth is a frequently reported side effect of Bupron SR. Insomnia or difficulty sleeping may occur in some patients. Headache often appears alongside the medication's use. Nausea can be experienced, especially during the initial treatment phase. Dizziness or lightheadedness is sometimes observed. Weight loss may be noted as appetite can be reduced. Constipation or gastrointestinal discomfort may develop.

Bupron SR is an extended-release form of bupropion used to treat depression and support smoking cessation. Patients may experience dry mouth, which can lead to increased thirst. Insomnia or difficulty sleeping is also reported, especially when the medication is taken later in the day. Some individuals notice a change in taste, often described as a metallic or bitter sensation. Weight loss can occur due to reduced appetite, while constipation is another possible gastrointestinal effect. Headache and mild dizziness are less frequent but have been noted in clinical observations.